PXT3003 (baclofen / sorbitol / naltrexone)
An investigational treatment for Charcot-Marie-Tooth Disease.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify PXT3003 (baclofen / sorbitol / naltrexone) wherever you encounter it, plus the key facts at a glance.
- Generic name
- PXT3003 (baclofen / sorbitol / naltrexone)
- Development code
- PXT3003
- Drug class
- Fixed-dose combination (PMP22-modulating)
- Manufacturer
- Pharnext (originally); Tasly (Tianshili) in China
- How it's taken
- Taken by mouth as a liquid solution twice daily.
A fixed-dose oral combination of three approved drugs in late-stage development for CMT1A, originally developed by Pharnext and now developed in China by Tasly (Tianshili).
- PXT3003 did not meet its primary endpoint in the Phase 3 PREMIER trial, but a Tianshili (Tasly) company submitted a New Drug Application in China in April 2025, based on a separate Chinese Phase 3 trial in 176 patients that met its main goal.
- U.S. development status remains uncertain.
We'll email you when the FDA acts on PXT3003 (baclofen / sorbitol / naltrexone) and when new trials for Charcot-Marie-Tooth Disease open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where PXT3003 (baclofen / sorbitol / naltrexone) fits
Investigational, not approved in the U.S. or EU.
- Has a regulatory submission active in China.
- Patients with CMT1A who are interested should monitor announcements from Tasly (Tianshili), the Hereditary Neuropathy Foundation, and the CMT Research Foundation rather than relying on press coverage of the failed primary endpoint, since regulatory paths in different countries may diverge.
How PXT3003 (baclofen / sorbitol / naltrexone) works
CMT1A is caused by an extra copy of the PMP22 gene. The body ends up making too much of the PMP22 protein, which disrupts the myelin coating around peripheral nerves and causes the slow progression of weakness, sensory loss, and foot drop characteristic of CMT.
PXT3003 is a fixed-dose oral combination of three already-approved medicines: low-dose baclofen (a muscle relaxant), sorbitol (a sugar alcohol used as an inactive ingredient in many medications), and naltrexone (a drug usually used in addiction medicine). Pharnext used a network-pharmacology approach to identify that this specific combination, at low doses, can lower PMP22 expression and protect myelin in animal models. None of the three drugs alone produces the effect.
The PREMIER Phase 3 trial in adults with CMT1A did not meet its primary endpoint. Tasly (Tianshili) filed a separate New Drug Application in China in April 2025, based on its own Chinese Phase 3 trial.
Clinical trial results
[PREMIER (NCT04762758)](https://clinicaltrials.gov/study/NCT04762758) was the pivotal Phase 3 trial of PXT3003 in adults with CMT1A. The trial enrolled 387 people aged 16 to 65 and ran a 15-month double-blind phase[5]. The primary endpoint was the Overall Neuropathy Limitations Scale (ONLS), a measure of everyday arm and leg disability.
People on placebo improved as much as people on PXT3003, which Pharnext said made the result hard to interpret. PXT3003 did not meet its primary endpoint per the company. Earlier, a 1-year Phase 2 trial in France (NCT01401257) and the Phase 3 PLEO-CMT trial (NCT02579759) had reported that the higher dose helped patients, which led to the pivotal study[8].
Main registered trial: NCT04762758 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.
Side effects and safety
Because PXT3003 is a combination of drugs that have been used safely for decades at higher doses, the individual safety profile of each component is well known. The combination has been studied in multiple Phase 2 and Phase 3 CMT1A trials. Reported side effects in clinical trials have generally been mild to moderate and consistent with what is known about baclofen, sorbitol, and naltrexone individually.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking PXT3003 (baclofen / sorbitol / naltrexone)
Taken by mouth as a liquid solution twice daily. In the PREMIER Phase 3 trial, the dose was 10mL in the morning and 10mL in the evening, with food[1]. The Chinese Phase 3 trial started at 5mL a dose for the first 2 weeks, then raised it to 10mL[8].
Development history
Pharnext, a French biotech, used a network-pharmacology platform to identify the PXT3003 combination as a CMT1A candidate. Multiple trials over a decade led to the Phase 3 PREMIER study. Pharnext ran out of funding and was placed in judicial liquidation by a Paris court on August 22, 2024[4]. Rights in China had been licensed in 2017 to GeneNet, a joint venture 65% owned by Tasly (Tianshili), which ran its own Chinese Phase 3 trial[6][7].
Tasly (Tianshili) filed a New Drug Application in China in April 2025, based on its Chinese Phase 3 trial, which was published in iScience in 2026. The UK MHRA granted PXT3003 a Promising Innovative Medicine (PIM) designation, which is an early-access regulatory designation. As of 2026, the U.S. FDA path forward remains uncertain.
Explore Charcot-Marie-Tooth Disease trials
Other Charcot-Marie-Tooth Disease treatments
Common questions about PXT3003 (baclofen / sorbitol / naltrexone)
▸What is PXT3003 (baclofen / sorbitol / naltrexone)?
A fixed-dose oral combination of three approved drugs in late-stage development for CMT1A, originally developed by Pharnext and now developed in China by Tasly (Tianshili). PXT3003 did not meet its primary endpoint in the Phase 3 PREMIER trial, but a Tianshili (Tasly) company submitted a New Drug Application in China in April 2025, based on a separate Chinese Phase 3 trial in 176 patients that met its main goal. U.S. development status remains uncertain.
▸How does PXT3003 (baclofen / sorbitol / naltrexone) work?
CMT1A is caused by an extra copy of the PMP22 gene. The body ends up making too much of the PMP22 protein, which disrupts the myelin coating around peripheral nerves and causes the slow progression of weakness, sensory loss, and foot drop characteristic of CMT.
PXT3003 is a fixed-dose oral combination of three already-approved medicines: low-dose baclofen (a muscle relaxant), sorbitol (a sugar alcohol used as an inactive ingredient in many medications), and naltrexone (a drug usually used in addiction medicine). Pharnext used a network-pharmacology approach to identify that this specific combination, at low doses, can lower PMP22 expression and protect myelin in animal models. None of the three drugs alone produces the effect.
The PREMIER Phase 3 trial in adults with CMT1A did not meet its primary endpoint. Tasly (Tianshili) filed a separate New Drug Application in China in April 2025, based on its own Chinese Phase 3 trial.
▸What are the side effects of PXT3003 (baclofen / sorbitol / naltrexone)?
Because PXT3003 is a combination of drugs that have been used safely for decades at higher doses, the individual safety profile of each component is well known. The combination has been studied in multiple Phase 2 and Phase 3 CMT1A trials. Reported side effects in clinical trials have generally been mild to moderate and consistent with what is known about baclofen, sorbitol, and naltrexone individually.
▸How is PXT3003 (baclofen / sorbitol / naltrexone) taken?
▸Is PXT3003 (baclofen / sorbitol / naltrexone) FDA approved?
PXT3003 (baclofen / sorbitol / naltrexone) is currently in phase 3 clinical trials for Charcot-Marie-Tooth Disease. It has not yet received FDA approval.
▸What is PXT3003?
PXT3003 is a fixed-dose oral combination of 3 already-approved medicines, low-dose baclofen, sorbitol, and naltrexone, in late-stage development for CMT1A. Pharnext identified the combination using a network-pharmacology approach, finding that at low doses it can lower PMP22 expression and protect myelin in animal models, while none of the 3 drugs alone produces the effect. It is taken by mouth as a liquid solution twice daily. [3]
▸Is PXT3003 FDA approved?
No, PXT3003 is not FDA-approved and is not approved in the EU. It is a Phase 3 drug whose U.S. path remains uncertain as of 2026, though Tasly (Tianshili) submitted a New Drug Application in China in April 2025 based on a Chinese Phase 3 trial in 176 patients that met its main goal. The UK MHRA has granted PXT3003 a Promising Innovative Medicine designation. [2][8]
▸What did the PXT3003 PREMIER trial show?
PREMIER (NCT04762758) was the pivotal Phase 3 trial of PXT3003 in 387 people aged 16 to 65 with CMT1A, with a 15-month double-blind phase and a primary endpoint on the ONLS disability scale. PXT3003 did not meet its primary endpoint, according to the company. An earlier Phase 2 trial and the Phase 3 PLEO-CMT trial had reported benefit at the higher dose, and a separate Chinese Phase 3 trial published in iScience in 2026 met its main goal. [1][3][8]
▸What are the side effects of PXT3003?
Because PXT3003 combines 3 drugs that have been used safely for decades at higher doses, the safety profile of each component is well known. Across multiple Phase 2 and Phase 3 CMT1A trials, reported side effects of PXT3003 have generally been mild to moderate and consistent with what is known about baclofen, sorbitol, and naltrexone individually. [1]
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- U.S. National Library of Medicine, ClinicalTrials.gov. Pivotal Phase III Study to Assess the Efficacy and Safety of PXT3003 in CMT1A Patients (PREMIER). https://clinicaltrials.gov/study/NCT04762758
- Hereditary Neuropathy Foundation. Pharnext Announces PXT3003 Granted Promising Innovative Medicine (PIM) Designation by UK MHRA. https://www.hnf-cure.org/research/pharnext-pim/
- Hereditary Neuropathy Foundation. Pharnext Unveils Latest Progress of PREMIER Phase III Clinical Trial for CMT1A. https://www.hnf-cure.org/triad/triad-therapeutics/pharnext/pharnext-unveils-the-latest-progress-of-the-premier-phase-iii-clinical-trial-for-cmt1a/
- Pharnext (AMF filing) · 2024-08-27. Pharnext announces the opening of judicial liquidation proceedings (AMF filing). https://echanges.dila.gouv.fr/OPENDATA/AMF/ACT/2024/08/FCACT070733_20240827.pdf
- Pharnext (AMF filing) · 2023-08-24. Pharnext reports the end of double-blind treatment in PREMIER trial, the pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A. https://echanges.dila.gouv.fr/OPENDATA/AMF/ACT/2023/08/FCACT065859_20230824.pdf
- Néovacs (Euronext) · 2026-01-14. Néovacs update on PXT3003. https://live.euronext.com/sites/default/files/company_press_releases/attachments/2026/01/14/cpr05_actus_95987_FR001400TG47.pdf
- ClinicalTrials.gov. A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A. https://clinicaltrials.gov/study/NCT05092841
- PubMed Central · 2026-08-26. A phase III clinical trial of PXT3003 in Chinese patients with Charcot-Marie-Tooth disease type 1A. https://pmc.ncbi.nlm.nih.gov/articles/PMC13544322/